The negative inotropic action of canrenone is mediated by L‐type calcium current blockade and reduced intracellular calcium transients
Open Access
- 28 August 2009
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 158 (2) , 580-587
Abstract
Background and purpose: Adding spironolactone to standard therapy in heart failure reduces morbidity and mortality, but the underlying mechanisms are not fully understood. We analysed the effect of canrenone, the major active metabolite of spironolactone, on myocardial contractility and intracellular calcium homeostasis.Experimental approach: Left ventricular papillary muscles and cardiomyocytes were isolated from male Wistar rats. Contractility of papillary muscles was assessed with force transducers, Ca2+transients by fluorescence and Ca2+fluxes by electrophysiological techniques.Key results: Canrenone (300–600 µmol·L−1) reduced developed tension, maximum rate of tension increase and maximum rate of tension decay of papillary muscles. In cardiomyocytes, canrenone (50 µmol·L−1) reduced cell shortening and L‐type Ca2+channel current, whereas steady‐state activation and inactivation, and reactivation curves were unchanged. Canrenone also decreased the Ca2+content of the sarcoplasmic reticulum, intracellular Ca2+transient amplitude and intracellular diastolic Ca2+concentration. However, the time course of [Ca2+]idecline during transients evoked by caffeine was not affected by canrenone.Conclusion and implications: Canrenone reduced L‐type Ca2+channel current, amplitude of intracellular Ca2+transients and Ca2+content of sarcoplasmic reticulum in cardiomyocytes. These changes are likely to underlie the negative inotropic effect of canrenone.Keywords
This publication has 33 references indexed in Scilit:
- Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1+minK channelsBritish Journal of Pharmacology, 2005
- Spironolactone and Its Main Metabolite, Canrenoic Acid, Block Human Ether-a-Go-Go–Related Gene ChannelsCirculation, 2003
- ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)Circulation, 2001
- Effect of Spironolactone and Its Metabolites on Contractile Property of Isolated Rat Aorta RingsJournal of Cardiovascular Pharmacology, 2000
- Aldosterone Upregulates Ca2+Current in Adult Rat CardiomyocytesCirculation Research, 1999
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Increase in the Basal Tone of Guinea Pig Thoracic Aorta Induced by Ouabain Is Inhibited by Spironolactone Canrenone and Potassium CanrenoateJournal of Cardiovascular Pharmacology, 1996
- Effects of Aldosterone and Spironolactone on the Isolated Perfused Rat HeartPharmacology, 1996
- Dependence of peak and mean ejection rate on load and effect of inotropic agents on the relationship between peak and left ventricular developed pressure — assessed in the isolated working rat heart and cardiac musclesInternational Journal of Cardiology, 1992
- Negative inotropic effects of aldosterone antagonists in isolated human and guinea-pig ventricular heart muscleJournal of Molecular Medicine, 1984